Raymond James Financial
EWTX icon

Raymond James Financial’s Edgewise Therapeutics EWTX Stock Holding History

Raymond James Financial’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9M Buy
317,565
+297,887
+1,514% +$10.3M ﹤0.01% 1931
2026
Q1 		$620K Sell
19,678
-1,931
-9% -$55.7K ﹤0.01% 4206
2025
Q4 		$536K Buy
21,609
+8,230
+62% +$165K ﹤0.01% 4222
2025
Q3 		$217K Buy
13,379
+11,821
+759% +$168K ﹤0.01% 4589
2025
Q2 		$20.4K Buy
+1,558
New +$22.5K ﹤0.01% 5590

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Raymond James Financial's EWTX Position: Q2 2026 in Review

Raymond James Financial increased its Edgewise Therapeutics (EWTX) stake by 1,514% in Q2 2026, buying an estimated $10.3M and bringing the position to 317,565 shares worth $12.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1931.

Raymond James Financial first reported a position in EWTX in Q2 2025 and has held it in 5 quarters since. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Raymond James Financial held 317,565 shares of Edgewise Therapeutics worth $12.9M as of Q2 2026.
  • Raymond James Financial bought 297,887 Edgewise Therapeutics shares in Q2 2026, an estimated $10.3M.
  • Edgewise Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #1931 holding.
  • Raymond James Financial first reported a position in Edgewise Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.